Bristol-Myers, Exelixis Phase 3 Kidney Cancer Study Meets Main Endpoints
April 20 2020 - 7:50AM
Dow Jones News
By Colin Kellaher
Bristol-Myers Squibb Co. and Exelixis Inc. on Monday said a
pivotal phase 3 study evaluating Opdivo in combination with
Cabometyx compared to sunitinib in previously untreated advanced or
metastatic renal-cell carcinoma met its key endpoints.
The companies said the study met the primary endpoint of
progression-free survival at final analysis, along with the
secondary endpoints of overall survival at a pre-specified interim
analysis and objective response rate.
The companies said the combination Bristol's Opdivo and
Exelixis' Cabometyx showed a favorable safety profile and could
become an important new first-line option for patients with
metastatic renal-cell carcinoma, the most common type of kidney
cancer in adults.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 20, 2020 07:35 ET (11:35 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2023 to Apr 2024
